Literature DB >> 34466034

The Effect of Parathyroid Gland Autotransplantation on Hypoparathyroidism After Thyroid Surgery for Papillary Thyroid Carcinoma.

Bin Wang1, Chun-Rong Zhu2, Xin-Min Yao1, Jian Wu1.   

Abstract

PURPOSE: There are some controversies over the relationship between parathyroid gland autotransplantation and permanent hypoparathyroidism. This study aimed to explore the relationship between parathyroid gland autotransplantation and postoperative hypoparathyroidism. PATIENTS AND METHODS: We performed a retrospective analysis of patients who underwent initial thyroid surgery for papillary thyroid carcinoma from January 2014 to December 2018. Patients were divided into 4 groups according to the number of autotransplanted parathyroid glands (group 1: 0 autotransplanted parathyroid gland, group 2: 1 autotransplanted parathyroid gland, group 3: 2 autotransplanted parathyroid glands, group 4: 3 autotransplanted parathyroid glands). Clinical data were analyzed among the four groups.
RESULTS: The more parathyroid glands were transplanted, the higher the incidence of immediate hypoparathyroidism was (group 1: 32.9%, group 2: 52.9%, group 3: 65.8%, group 4: 82.4%; Pgroup 1 vs group 2 < 0.001, Pgroup 2 vs group 3 = 0.012, Pgroup 3 vs group 4 = 0.17). Parathyroid gland autotransplantation did not affect the incidence of permanent hypoparathyroidism (group 1: 1.4%, group 2: 1.3%, group 3: 0.9%, group 4: 0%; Pgroup 1 vs group 2 > 0.99, Pgroup 2 vs group 3 > 0.99, Pgroup 3 vs group 4 > 0.99).
CONCLUSION: The number of autotransplanted parathyroid glands was positively associated with the incidence of postoperative immediate hypoparathyroidism. Parathyroid gland autotransplantation was not associated with permanent hypoparathyroidism.
© 2021 Wang et al.

Entities:  

Keywords:  autotransplantation; hypoparathyroidism; parathyroid gland; thyroid surgery

Year:  2021        PMID: 34466034      PMCID: PMC8402957          DOI: 10.2147/CMAR.S323742

Source DB:  PubMed          Journal:  Cancer Manag Res        ISSN: 1179-1322            Impact factor:   3.989


Introduction

Surgery was widely accepted as the primary therapy method for thyroid carcinoma.1,2 Among the complications of thyroid surgery, postoperative hypoparathyroidism was the most common.3,4 The incidence of transient hypoparathyroidism ranged from 10.8% to 64.4%, and the incidence of permanent hypoparathyroidism varied from 0 to 31.1% across different researches.5–8 Hypoparathyroidism was the consequence of the reduction of the functional parathyroid parenchyma for mechanical or thermal trauma, devascularization, and inadvertent resection.9–11 Transient hypoparathyroidism may prolong hospitalization and increase the overall costs, and permanent hypoparathyroidism will severely affect the quality of life.9,12,13 In order to protect the parathyroid function, meticulous capsule dissection was used to preserve parathyroid glands and their blood supply, and autotransplantation was performed to save the function of parathyroid glands that were not able to be preserved in site.14,15 In recent years, routine parathyroid gland autotransplantation (PGA) was suggested to prevent permanent hypoparathyroidism because of its’ predictable outcome.16,17 However, some studies discovered that PGA increased the risk of transient hypoparathyroidism and had no effects on permanent hypoparathyroidism.18,19 While some researchers indicated the incidence of hypoparathyroidism was associated with the number of autotransplanted parathyroid glands (APGs).10,13,20 In consideration of these controversies, we conducted the study to explore the relationship between PGA and postoperative hypoparathyroidism, investigate the influence of the number of APG in hypoparathyroidism, and identify the risk factors for postoperative hypoparathyroidism.

Patients and Methods

We performed a retrospective analysis of patients who underwent thyroid surgery for papillary thyroid carcinoma at our institution from January 2014 to December 2018. Patients who met all the following criteria were included: 1) patients who underwent the initial thyroid surgery; 2) the minimal surgical extent consisted of total thyroidectomy (TT) and bilateral central lymph node dissection (BCND). The exclusion criteria included: 1) patients who had undergone neck surgery; 2) patients who had received neck radiation therapy; 3) patients who suffered from parathyroid diseases at the same time; 4) patients whose preoperative serum parathyroid hormone (PTH) and/or calcium was abnormal; 5) patients who received calcium supplementation for other causes; 6) patients with the incomplete medical record; 7) patients who lost to follow-up in 6 months. The study was approved by the Medical Ethics Committee of Chengdu Third People’s Hospital. And informed consent about the application of clinical data to medical research was obtained from all the subjects. The surgical procedures were the same as those described by Su et al.21 Two professional thyroid surgeons (Wu J and Yao X) performed all procedures. Every parathyroid gland and its’ blood supply were attempted to identify and preserve during surgery. Excisional thyroid and central tissue were routinely examined for any potential inadvertently excisional parathyroid glands. When a parathyroid gland was non-viable or found in the intraoperative specimens, it was fragmented into 1-mm pieces and inserted into 3–4 muscular pockets in the contralateral sternocleidomastoid muscle after histological confirmation by intraoperative frozen biopsy. The inadvertently excisional parathyroid gland (IEPG) was defined as the presence of parathyroid tissue in the postoperative specimens according to the pathologist. Standardized perioperative management was applied to all patients with thyroid carcinoma. Neck ultrasound, laryngoscopy, thyroid function, serum PTH and calcium were routine preoperative assessments. Neck computerized tomography was used when the tumor was clinical suspicion for the advanced stage. Serum PTH and calcium were measured at 1 day, 1 month, 3 months, 6 months postoperatively. Intravenous calcium supplementation (calcium gluconate 10%, 20 mL) was routinely administered at the end of surgery and 1 day postoperatively. After that, oral calcium was administered according to the postoperative serum PTH and symptoms. In these patients with mild hypoparathyroidism (PTH: 1.0 ~ 1.6 pmol/l), oral calcium supplementation of 1200 mg/day was prescribed. As for patients with medium hypoparathyroidism (PTH: 0.5 ~ 1.0 pmol/l), the calcium of 1200 mg/day and calcitriol of 1.0 ug/day were taken. And calcium of 1800 g/day and calcitriol 1.5 ug/day were administered to the patients with severe hypoparathyroidism (PTH < 0.5 pmol/l). If patients suffered from mild symptoms, such as numbness of fingers, an upgraded level of strategy of calcium supplementation based on the level of serum PTH would be taken. While, intravenous calcium supplement was administered to the patients with severe symptoms, for example, spasms. Patients were discharged when their serum calcium was normal (2.1–2.7 mmol/l). Hypoparathyroidism was defined as a serum PTH level of less than 1.6 pmol/l (normal range: 1.6–6.9 pmol/L) or presence of symptoms requiring calcium supplementation regardless of the PTH values. Hypocalcemia was defined as the less normal level in serum calcium (normal range: 2.1–2.7 mmol/l). Postoperative immediate hypoparathyroidism was defined as hypoparathyroidism at 1 day postoperatively. Protracted hypoparathyroidism was defined when hypoparathyroidism occurred at 1 month postoperatively. It was regarded as permanent hypoparathyroidism when hypoparathyroidism lasted for more than 6 months. The collected data included the following information: the demographic characteristics, preoperative assessment, details of surgical extent, number of the APG and IEPG, pathologic report, the incidence of postoperative hypoparathyroidism, preoperative and postoperative serum PTH and calcium, and tumor characteristics. And according to the number of APG, patients were divided into 4 groups: group 1 (0 APG), group 2 (1 APG), group 3 (2 APGs), group 4 (3 APGs). The number of the parathyroid gland in site (ISPG) resulted from the formula: 4 minus the number of APG minus the number of IEPG. The statistical analyses were conducted with SPSS version 23.0 software (SPSS Inc, Chicago, IL). Continuous data were expressed as mean ± standard deviation (SD). Student’s t-test or Mann–Whitney test was used for continuous variables, and Pearson’s Chi-square test or Fisher’s exact test was used for categorical variables. When the variables were potentially statistically significant in univariate analysis (p < 0.1), they were analyzed by multivariable statistical analysis with binary logistic regression analysis to identify the risk factors for postoperative immediate and permanent hypoparathyroidism. Statistical significance was set at P < 0.05.

Results

A total of 658 patients were included in the retrospective cohort study. Among them, 216, 314, 111, and 17 patients underwent autotransplantation of 0, 1, 2, and 3 parathyroid glands, respectively. There were no significant differences in the demographic characteristics (age, gender, body mass index), comorbidities (hypertension, diabetes, hyperthyroidism, hypothyroidism, and nodular goiter), preoperative serum PTH and calcium, tumor characteristics, and postoperative other complications (transient hoarseness, wound infection, postoperative bleeding, and chylous fistula) between group 1 and group 2, between group 2 and group 3, between group 3 and group 4 (Table 1). The gross extrathyroidal extension of the tumor, use of carbon nanoparticles, and more lymph nodes (> 10) were dissected in the central zone were associated with PGA (P = 0.037, P < 0.001, P < 0.001, respectively; Table 1).
Table 1

The Characteristics Among 4 Groups with Different Number of Autotransplanted Parathyroid Gland

VariablesGroup 1 (216)Group 2 (314)Group 3 (111)Group 4 (17)P1vs2P2vs3P3vs4
Gender (F/M)160/56219/9577/3412/50.280.940.92
Age (years)41.8±13.141.3±12.542.1±12.238.8±11.30.640.540.3
BMI (kg/m2)22.9±3.423.4±3.523.1±3.423.2±4.30.090.420.89
Hypertension21391210.340.650.85
Diabetes511220.430.570.09
Hyperthyroidism1012200.650.47>0.99
Hypothyroidism74100.21>0.99>0.99
Hashimoto’s Thyroiditis65963670.910.720.48
Nodular goiter11717663120.670.90.28
Preoperative serum PTH (pmol/l)5.34±1.945.77±2.225.72±2.135.47±2.030.150.830.66
Preoperative serum calcium (mmol/l)2.33±0.12.34±0.362.32±0.112.31±0.130.680.660.68
Carbon nanoparticles17628910013<0.0010.530.22
Preoperative lymphadenectasis in the central zone521024980.140.0270.82
Largest size of lymph nodes (mm)12.8±5.312±4.613.5±6.413.1±6.10.380.140.87
Surgical extent0.120.180.68
TT+BCND1792377512
TT+BCND+ULND3265285
TT+BCND+BLND51280
Largest tumor size (mm)16±13.215.8±9.916.8±10.814.1±5.00.880.380.1
Tumor location (upper/middle/lower/isthmus)58/84/62/1287/124/82/2122/50/24/156/5/3/30.890.0510.55
Bilateral lobe tumors50873110.240.960.1
Multifocal tumors551003440.110.810.55
Gross extrathyroidal extension26593020.0370.070.29
Number of lymph nodes in the central zone12.8±6.313.8±6.714.6±7.014.9±7.20.090.280.86
≤10/>10126/9088/22629/822/15<0.0010.70.33
Number of metastatic lymph nodes in central zone3.5±3.94.1±4.64.6±4.74.4±4.70.130.270.86
≤5/>5154/62204/11067/4413/40.130.390.2
Pathological T classification (T1/T2/T3a/T3b/T4)160/24/6/23/3210/39/6/40/1965/15/1/19/1113/2/0/2/00.070.360.12
Pathological N classification (N0/N1)58/15875/23922/894/130.440.380.98
AJCC stage (I~II/ III~IV)215/1308/610/117/00.250.78>0.99
Inadvertently resected PG25421300.540.650.29
Transient hoarseness59600.70.240.65
Wound infection410500.340.73>0.99
Postoperative bleeding2410>0.99>0.99>0.99
Chylous fistula02400.510.043>0.99

Notes: P1vs2, Group 1 vs Group 2; P2vs3, Group 2 vs Group 3; P3vs4, Group 3 vs Group 4.

Abbreviations: F, female; M male; BMI body mass index; PTH parathyroid hormone; TT total thyroidectomy; BCND bilateral central lymph node dissection; ULND unilateral neck lymph node dissection (compartments II–V); BLND bilateral neck lymph node dissection (compartments II–V); PG, parathyroid gland.

The Characteristics Among 4 Groups with Different Number of Autotransplanted Parathyroid Gland Notes: P1vs2, Group 1 vs Group 2; P2vs3, Group 2 vs Group 3; P3vs4, Group 3 vs Group 4. Abbreviations: F, female; M male; BMI body mass index; PTH parathyroid hormone; TT total thyroidectomy; BCND bilateral central lymph node dissection; ULND unilateral neck lymph node dissection (compartments II–V); BLND bilateral neck lymph node dissection (compartments II–V); PG, parathyroid gland. As shown in Table 2, the more parathyroid glands were transplanted, the lower level the serum PTH at 1 day postoperatively was (group 1: 2.36 ± 1.38, group 2: 1.79 ± 1.18, group 3: 1.44 ± 0.95, group 4: 1.1 ± 0.81; Pgroup 1 vs group 2 < 0.001, Pgroup 2 vs group 3 = 0.002, Pgroup 3 vs group 4 = 0.16), the higher the incidence of immediate hypoparathyroidism become (group 1: 32.9%, group 2: 52.9%, group 3: 65.8%, group 4: 82.4%; Pgroup 1 vs group 2 < 0.001, Pgroup 2 vs group 3 = 0.012, Pgroup 3 vs group 4 = 0.17), and the longer the stay in hospital got (group 1: 4.2 ± 2.2, group 2: 4.9 ± 2.9, group 3: 5.8 ± 5.4, group 4: 5.7 ± 2.8; Pgroup 1 vs group 2 = 0.008, Pgroup 2 vs group 3 = 0.039, Pgroup 3 vs group 4 = 0.91). However, PGA did not affect the incidence of protracted hypoparathyroidism (group 1: 5.1%, group 2: 6.4%, group 3: 3.6%, group 4: 5.9%; Pgroup 1 vs group 2 = 0.54, Pgroup 2 vs group 3 = 0.28, Pgroup 3 vs group 4 = 0.52; Table 2) and permanent hypoparathyroidism (group 1: 1.4%, group 2: 1.3%, group 3: 0.9%, group 4: 0%; Pgroup 1 vs group 2 > 0.99, Pgroup 2 vs group 3 > 0.99, Pgroup 3 vs group 4 > 0.99; Table 2).
Table 2

The Influence of Different Numbers of Autotransplanted Parathyroid Gland

VariablesGroup 1 (216)Group 2 (314)Group 3 (111)Group 4 (17)P1vs2P2vs3P3vs4
Postoperative PTH (pmol/l)
1 day2.36±1.381.79±1.181.44±0.951.1±0.81<0.0010.0020.16
1 month3.79±1.753.6±1.593.73±1.512.85±1.320.240.510.049
6 months3.99±1.733.81±1.73.8±1.232.95±1.270.540.950.2
Postoperative immediate hypoparathyroidism (%)71 (32.9)163 (51.9)73 (65.8)14 (82.4)<0.0010.0120.17
Protracted hypoparathyroidism (%)11 (5.1)20 (6.4)4 (3.6)1 (5.9)0.540.280.52
Permanent hypoparathyroidism (%)3 (1.4)4 (1.3)1 (0.9)0 (0)>0.99>0.99>0.99
Postoperative serum calcium (mmol/l)
1 day2.16±0.152.11±0.152.06±0.192.08±0.1<0.0010.0210.79
1 month2.3±0.152.29±0.192.33±0.332.24±0.10.660.120.27
6 months2.26±0.22.23±0.182.26±0.152.26±0.130.470.570.99
Postoperative immediate hypocalcemia (%)69 (31.9)146 (46.5)56 (50.5)8 (47.1)0.0010.470.8
Protracted hypocalcemia (%)18 (8.3)30 (9.6)4 (3.6)1 (5.9)0.630.0470.52
Permanent hypocalcemia (%)2 (0.9)7 (2.2)1 (0.9)0 (0)0.410.62>0.99
Postoperative length of stay (days)4.2±2.24.9±2.95.8±5.45.7±2.80.0080.0390.91

Abbreviation: PTH, parathyroid hormone.

The Influence of Different Numbers of Autotransplanted Parathyroid Gland Abbreviation: PTH, parathyroid hormone. Table 3 showed the details of the different management of parathyroid glands. A total of 587 parathyroid glands were autotransplanted among 442 patients, and 83 parathyroid glands were inadvertently resected among 80 patients. There were significant differences in the incidences of postoperative immediate hypoparathyroidism among patients with different numbers of APG when they did not undergo inadvertent parathyroid gland resection (0 APG: 28.8%, 1 APG 51.1%, 2 APG 63.3%, 3 APG 82.4%, P < 0.001; Table 3). When one parathyroid gland was inadvertently resected, no significant differences in the incidence of postoperative immediate, protracted and permanent hypoparathyroidism were found among patients with different numbers of APG. When patients did not undergo PGA, the incidences of postoperative immediate hypoparathyroidism were significantly different among patients with different numbers of IEPG (0 IEPG:28.8%, 1 IEPG: 59.1%, 2 IEPGs: 100%, P = 0.001; Table 3), while differences were not found in the incidence of protracted and permanent hypoparathyroidism. There also were no significant differences in incidence of postoperative immediate, protracted and permanent hypoparathyroidism between patients with and without one IEPG after undergoing PGA.
Table 3

Comparison Among Groups with Different Management of Parathyroid Gland

The Number of Parathyroid GlandsNPostoperative Immediate Hypoparathyroidism (%)Protracted Hypoparathyroidism (%)Permanent Hypoparathyroidism (%)
0 APG21671(32.9)11(5.1)3(1.4)
4 ISPG19155(28.8)9(4.7)2(1.0)
3 ISPG+1 IEPG2213(59.1)2(9.1)1(4.5)
2 ISPG+2 IEPG33(100)0(0)0(0)
P0APG0.0010.630.41
1 APG314163(51.9)20(6.4)4(1.3)
3 ISPG272139(51.1)18(6.6)3(1.1)
2 ISPG+1 IEPG4224(57.1)2(4.8)1(2.4)
P1APG0.470.910.44
2 APG11173(65.8)4(3.6)1(0.9)
2 ISPG9862(63.3)3(3.1)0(0)
1 ISPG+1 IEPG1311(84.6)1(7.7)1(7.7)
P2APG0.210.400.12
3 APG+1 ISPG1714(82.4)1(5.9)0(0)
P4PGs<0.0010.570.74
P3PGs0.190.790.68

Notes: P0APG, P value of comparison among rates of groups without autotransplanted parathyroid gland; P1APG, P value of comparison among rates of groups with 1 autotransplanted parathyroid gland; P2APG, P value of comparison among rates of groups with 2 autotransplanted parathyroid glands; P4PGs, P value of comparison among rates of groups without inadvertently resected parathyroid gland; P3PGs, P value of comparison among rates of groups with one inadvertently resected parathyroid gland.

Abbreviation: APG autotransplanted parathyroid gland; ISPG parathyroid gland in site; IEPG inadvertently excisional parathyroid gland.

Comparison Among Groups with Different Management of Parathyroid Gland Notes: P0APG, P value of comparison among rates of groups without autotransplanted parathyroid gland; P1APG, P value of comparison among rates of groups with 1 autotransplanted parathyroid gland; P2APG, P value of comparison among rates of groups with 2 autotransplanted parathyroid glands; P4PGs, P value of comparison among rates of groups without inadvertently resected parathyroid gland; P3PGs, P value of comparison among rates of groups with one inadvertently resected parathyroid gland. Abbreviation: APG autotransplanted parathyroid gland; ISPG parathyroid gland in site; IEPG inadvertently excisional parathyroid gland. The analyses of potential risk factors for postoperative immediate and permanent hypoparathyroidism were showed in Table 4. Gender, diabetes, hyperthyroidism, preoperative lymphadenectasis in the central zone, surgical extent, PGA, and inadvertently resected parathyroid gland might be associated with postoperative immediate hypoparathyroidism. And use of carbon nanoparticles and inadvertently resected parathyroid glands might affect permanent hypoparathyroidism. Multivariate analysis demonstrated that female gender (OR = 1.45; 95% CI 1.02–2.06; p = 0.038), PGA (OR = 2.74; 95% CI 1.94–3.87; p < 0.001) and inadvertently resected parathyroid gland (OR = 2.02; 95% CI 1.23–3.32; p = 0.006) were independent risk factors for postoperative immediate hypoparathyroidism, and nonuse of carbon nanoparticles (OR = 0.23; 95% CI 0.05–0.99; p = 0.049) and inadvertently removed parathyroid gland (OR = 4.36; 95% CI 1.01–18.79; p = 0.049) were independent risk factors for permanent hypoparathyroidism (Table 5).
Table 4

Univariate Analysis of Risk Factors for the Postoperative Immediate and Permanent Hypoparathyroidism

VariablesPostoperative Immediate HypoparathyroidismPermanent Hypoparathyroidism
No (337)Yes (321)PNo (650)Yes (8)P
Gender (F/M)229/108239/820.066461/1897/10.53
Age (years)41.8±12.541.2±12.70.5041.5±12.542.8±17.30.78
BMI (kg/m2)23.2±3.523.2±3.40.7823.2±3.423.2±4.2>0.99
Hypertension42310.25721>0.99
Diabetes6140.054200>0.99
Hyperthyroidism1770.050240>0.99
Hypothyroidism660.93120>0.99
Hashimoto’s Thyroiditis1041000.9420130.99
Nodular goiter1831850.3936440.74
Preoperative serum PTH (pmol/l)5.68±2.065.48±2.190.245.59±2.135.17±1.930.58
Preoperative serum calcium (mmol/l)2.32±0.122.34±0.360.182.33±0.272.3±0.160.78
Carbon nanoparticles3022760.1557350.062
Preoperative lymphadenectasis in the central zone961150.04420740.48
Largest size of lymph nodes (mm)12.6±5.512.6±5.20.9012.5±5.316±6.20.20
Surgical extent0.0550.29
TT+BCND2712345005
TT+BCND+ULND57711262
TT+BCND+BLND916241
Largest tumor size (mm)15.6±10.216.4±12.10.3415.9±10.826.1±27.40.33
Tumor location (upper/middle/lower/isthmus)93/109/115/2081/119/91/300.13170/227/204/494/1/2/10.49
Bilateral lobe tumors80890.2416810.65
Multifocal tumors94990.4119210.51
Gross extrathyroidal extension56610.4211520.94
Number of lymph nodes in the central zone13.6±6.713.5±6.60.8613.6±6.614.4±10.10.74
≤10/>10103/23495/2260.78194/4564/40.4
Number of metastatic lymph nodes in central zone3.8±4.44.2±4.50.274±4.43.8±3.40.89
≤5/>5225/112213/1080.91433/2175/3>0.99
Pathological T classification (T1~T2/T3~T4)277/60251/700.2523/1275/30.41
Pathological N classification (pN0/pN1)89/24870/2510.17158/4921/70.72
AJCC stage (I~II/III~IV)331/6319/20.29642/88/0>0.99
PGA192250<0.00143750.72
Inadvertently resected PG29510.0047730.062
Transient hoarseness1190.73200>0.99
Wound infection1090.9190>0.99
Postoperative bleeding43>0.9970>0.99
Chylous fistula33>0.9960>0.99

Abbreviations: F, female; M male; BMI body mass index; PTH parathyroid hormone; TT total thyroidectomy; BCND bilateral central lymph node dissection; ULND unilateral neck lymph node dissection (compartments II–V); BLND bilateral neck lymph node dissection (compartments II–V); PG, parathyroid gland.

Table 5

Multivariate Analysis of Risk Factors for Postoperative Immediate and Permanent Hypoparathyroidism

VariablesPostoperative Immediate Hypoparathyroidism (G=866.112,P<0.001)Permanent Hypoparathyroidism (G=79.766,P<0.001)
OR95% CIPOR95% CIP
Female1.451.02–2.060.038
Carbon nanoparticles0.230.05–0.990.049
PGA2.741.94–3.87<0.001
Inadvertently resected PG2.021.23–3.320.0064.361.01–18.790.049

Abbreviations: PGA, parathyroid gland autotransplantation; PG, parathyroid gland.

Univariate Analysis of Risk Factors for the Postoperative Immediate and Permanent Hypoparathyroidism Abbreviations: F, female; M male; BMI body mass index; PTH parathyroid hormone; TT total thyroidectomy; BCND bilateral central lymph node dissection; ULND unilateral neck lymph node dissection (compartments II–V); BLND bilateral neck lymph node dissection (compartments II–V); PG, parathyroid gland. Multivariate Analysis of Risk Factors for Postoperative Immediate and Permanent Hypoparathyroidism Abbreviations: PGA, parathyroid gland autotransplantation; PG, parathyroid gland.

Discussions

PGA is the exclusive way to restore the function of the parathyroid gland that could not be preserved in site. However, some researchers found that the function of the APG was not always able to recover to the preoperative level.22–24 Even so, some surgeons discovered PGA could reduce the incidence of permanent hypoparathyroidism and thus suggested routinely performed it.16,17 However, some other studies suggested that PGA did not affect, even increase the incidence of permanent hypoparathyroidism.8,25 In the present study, use of carbon nanoparticles, gross extrathyroidal extension of the tumor, and more excisional lymph nodes (>10) in the central zone increased the incidence of PGA. In recent decades, carbon nanoparticles has been used as a tracer to stain the thyroid and lymph system during thyroid surgery.26,27 Because it did not stain the parathyroid glands, carbon nanoparticles could help to identify them, which might assist to discover the parathyroid gland in the specimens during surgery and thus increase the number of APG.26,27 Gross extrathyroidal extension of the tumor might lead to increased difficulty in preserving parathyroid glands in their site and protecting their blood supply. More excisional lymph nodes meant a larger surgery extent, which would be an adverse factor in protecting the parathyroid gland. Several studies demonstrated that the value of serum PTH at 1 day postoperatively decreased and the incidence of postoperative transient hypoparathyroidism increased as the parathyroid gland was transplanted.10,13,28 The current research was consistent with previous researches. It took at least 4 weeks for the APG to recover full function.29,30 So, the functional parathyroid gland tissue would reduce during this period when the number of APG increased. The number of APG did not significantly affect the incidence of postoperative protracted and permanent hypoparathyroidism. It might be the reason that almost all the patients had three or more functional parathyroid glands regardless of whether they were preserved in site or autotransplanted. Patients with three or more ISPGs scarcely underwent permanent hypoparathyroidism, nor did patients with 3 or more APGs.3,31 It was also controversial whether the parathyroid gland with potential injury of blood supply (parathyroid gland with some degree of discolored) should be preserved in site or autotransplanted. Su et al and Lorente-Poch et al indicated that when three parathyroid glands were preserved in site, the fourth parathyroid gland did not significantly affect the incidence of permanent hypoparathyroidism regardless of whether it was preserved in site or autotransplanted.11,15 This study suggested when the number of functional parathyroid glands was equal, no matter what method was used to protect their function (preserved in site or autotransplanted), the incidences of protracted and permanent hypoparathyroidism were similar. This phenomenon might attribute to the fact that at least one parathyroid gland was preserved in site and the number of functional parathyroid glands was more than three. Song and his colleagues demonstrated that one ISPG was sufficient to prevent permanent hypoparathyroidism.32 In the current study, the incidence of postoperative immediate hypoparathyroidism was 48.8%, and the complication prolonged the postoperative length of stay (5.5 ± 3.8 days vs 4.3 ± 2.6 days, P < 0.001). Female gender was one of the risk factors for postoperative immediate hypoparathyroidism in the study, which had been reported in the previous study.33 Some studies suggested the proportions of parenchymal fat and stromal fat in parathyroid tissue were different between males and females.34,35 And Dufour et al confirmed that the weight of the parathyroid gland in men was higher than that in women.35 Besides, PTH secretion was affected by sex steroids, which were different between males and females.36,37 It was also speculated that the gender disparity might lead to the difference in regulators of monoclonal proliferation and mitosis of parathyroid tissue and the difference in the anatomy of the parathyroid gland.37,38 As for other risk factors for immediate hypoparathyroidism, PGA and inadvertently resected parathyroid gland both led to the reduction of postoperative real-time functional parathyroid parenchyma. The study also suggested that the use of carbon nanoparticles was the protective factor for permanent hypoparathyroidism. Several studies indicated that carbon nanoparticles could assist to identify the parathyroid gland and decrease the incidence of the inadvertently resected parathyroid gland.26,27 Consistent with previous researches, inadvertently resected parathyroid gland increased the incidence of permanent hypoparathyroidism.39,40 There were several limitations in this study. First, the data were retrospectively analyzed, and some selective biases were inevitable. Second, the APG could not be evaluated objectively. Third, the sample size of the study, especially permanent hypoparathyroidism, was small. Research with larger sample size and objective evaluation indicators, such as parathyroid glands were transplanted in the forearm, was necessary to be conducted to verify the result in this study.

Conclusions

In conclusion, PGA increases the risk of postoperative immediate hypoparathyroidism, and the more parathyroid glands are transplanted, the more likely the immediate hypoparathyroidism occurs. Besides, female gender and inadvertently resected parathyroid gland may increase the risk of immediate hypoparathyroidism. PGA does not affect permanent hypoparathyroidism when three or more functional parathyroid glands are reserved regardless of whether they are preserved in site or autotransplanted. The use of carbon nanoparticles could help to reduce the incidence of permanent hypoparathyroidism and the parathyroid gland should be identified as much as possible to avoid being inadvertently resected.
  38 in total

Review 1.  Expert consensus statement on parathyroid protection in thyroidectomy.

Authors:  Jingqiang Zhu; Wen Tian; Zhengang Xu; Kewei Jiang; Hui Sun; Ping Wang; Tao Huang; Zhuming Guo; Hao Zhang; Shaoyan Liu; Yanjun Zhang; Ruochuan Cheng; Daiwei Zhao; Youben Fan; Xiaoxi Li; Jianwu Qin; Wenxin Zhao; Anping Su
Journal:  Ann Transl Med       Date:  2015-09

2.  Failure of fragmented parathyroid gland autotransplantation to prevent permanent hypoparathyroidism after total thyroidectomy.

Authors:  Leyre Lorente-Poch; Juan Sancho; Jose Luis Muñoz; Lander Gallego-Otaegui; Carlos Martínez-Ruiz; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2017-01-07       Impact factor: 3.445

Review 3.  A Meta-analysis of Carbon Nanoparticles for Identifying Lymph Nodes and Protecting Parathyroid Glands during Surgery.

Authors:  Yin Li; Wen-Hua Jian; Zhu-Ming Guo; Qiu-Li Li; Shao-Jian Lin; Hai-Yan Huang
Journal:  Otolaryngol Head Neck Surg       Date:  2015-04-20       Impact factor: 3.497

4.  Outcome of protracted hypoparathyroidism after total thyroidectomy.

Authors:  A Sitges-Serra; S Ruiz; M Girvent; H Manjón; J P Dueñas; J J Sancho
Journal:  Br J Surg       Date:  2010-11       Impact factor: 6.939

5.  Assessment of parathyroid autotransplantation for preservation of parathyroid function after total thyroidectomy.

Authors:  Magdy I El-Sharaky; Mohamed R Kahalil; Ola Sharaky; Mahmoud F Sakr; Geylan A Fadaly; Habashi A El-Hammadi; Mohamed M Moussa
Journal:  Head Neck       Date:  2003-10       Impact factor: 3.147

6.  Latent hypoparathyroidism in patients with autotransplanted parathyroid glands.

Authors:  H Salander; L E Tisell
Journal:  Am J Surg       Date:  1980-03       Impact factor: 2.565

Review 7.  A systematic review and meta-analysis of prophylactic central neck dissection on short-term locoregional recurrence in papillary thyroid carcinoma after total thyroidectomy.

Authors:  Brian Hung-Hin Lang; Sze-How Ng; Lincoln L H Lau; Benjamin J Cowling; Kai Pun Wong; Koon Yat Wan
Journal:  Thyroid       Date:  2013-08-28       Impact factor: 6.568

8.  Routine parathyroid autotransplantation during total thyroidectomy: a procedure with predictable outcome.

Authors:  Nisar Ahmed; Mahmud Aurangzeb; Mohammad Muslim; Mohammad Zarin
Journal:  J Pak Med Assoc       Date:  2013-02       Impact factor: 0.781

9.  Children are at a high risk of hypocalcaemia and hypoparathyroidism after total thyroidectomy.

Authors:  Mechteld de Jong; Hassan Nounou; Virginia Rozalén García; Ioannis Christakis; Caroline Brain; Tarek E Abdel-Aziz; Richard J Hewitt; Tom R Kurzawinski
Journal:  J Pediatr Surg       Date:  2019-07-19       Impact factor: 2.545

10.  Relationship between hypoparathyroidism and the number of parathyroid glands preserved during thyroidectomy.

Authors:  Chang Myeon Song; Joo Hwan Jung; Yong Bae Ji; Hyun Jung Min; You Hern Ahn; Kyung Tae
Journal:  World J Surg Oncol       Date:  2014-07-07       Impact factor: 2.754

View more
  3 in total

1.  Factors in the occurrence and restoration of hypoparathyroidism after total thyroidectomy for thyroid cancer patients with intraoperative parathyroid autotransplantation.

Authors:  Dengwei Lu; Enjie Tang; Supeng Yin; Junping Zhu; Hongbiao Mo; Ziying Yi; Fan Chai; Yizeng Sun; Yao Li; Tingjie Yin; Zeyu Yang; Fan Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

2.  Clinical application of parathyroid autotransplantation in endoscopic radical resection of thyroid carcinoma.

Authors:  Qi Zhang; Kun-Peng Qu; Ze-Sheng Wang; Jing-Wei Gao; Yu-Peng Zhang; Wei-Jia Cao
Journal:  Front Oncol       Date:  2022-08-04       Impact factor: 5.738

3.  The Reality of Hypoparathyroidism After Thyroidectomy: Which Risk Factors are Effective? Single-Center Study.

Authors:  Ismail Ethem Akgun; Mehmet Taner Unlu; Nurcihan Aygun; Mehmet Kostek; Aydin Eray Tufan; Ceylan Yanar; Ali Yuksel; Elif Baran; Yasin Cakir; Mehmet Uludag
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2022-06-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.